Terms: = Breast cancer AND TRA AND Prognosis
4 results:
1. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract] [Full Text] [Related]
2. Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.
Xiao H; Jensen PE; Chen X
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491952
[TBL] [Abstract] [Full Text] [Related]
3. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Kanomata N; Kurebayashi J; Moriya T
Med Mol Morphol; 2019 Jun; 52(2):106-113. PubMed ID: 30317526
[TBL] [Abstract] [Full Text] [Related]
4. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
[TBL] [Abstract] [Full Text] [Related]